Quest Diagnostics Incorporated (DGX)
NYSE: DGX · IEX Real-Time Price · USD
136.64
-0.45 (-0.33%)
At close: Jul 2, 2024, 4:00 PM
137.62
+0.98 (0.72%)
After-hours: Jul 2, 2024, 7:59 PM EDT
Quest Diagnostics Employees
Quest Diagnostics had 48,000 employees as of December 31, 2023. The number of employees decreased by 1,000 or -2.04% compared to the previous year.
Employees
48,000
Change (1Y)
-1,000
Growth (1Y)
-2.04%
Revenue / Employee
$193,479
Profits / Employee
$17,625
Market Cap
15.18B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 48,000 | -1,000 | -2.04% |
Dec 31, 2022 | 49,000 | 0 | - |
Dec 31, 2021 | 49,000 | 0 | - |
Dec 31, 2020 | 49,000 | 2,000 | 4.26% |
Dec 31, 2019 | 47,000 | 1,000 | 2.17% |
Dec 31, 2018 | 46,000 | 1,000 | 2.22% |
Dec 31, 2017 | 45,000 | 2,000 | 4.65% |
Dec 31, 2016 | 43,000 | -1,000 | -2.27% |
Dec 31, 2015 | 44,000 | -1,000 | -2.22% |
Dec 31, 2014 | 45,000 | 4,000 | 9.76% |
Dec 31, 2013 | 41,000 | 0 | - |
Dec 31, 2012 | 41,000 | -1,000 | -2.38% |
Dec 31, 2011 | 42,000 | 0 | - |
Dec 31, 2010 | 42,000 | -1,000 | -2.33% |
Dec 31, 2009 | 43,000 | 200 | 0.47% |
Dec 31, 2008 | 42,800 | -700 | -1.61% |
Dec 31, 2007 | 43,500 | 2,500 | 6.10% |
Dec 31, 2006 | 41,000 | -500 | -1.20% |
Dec 31, 2005 | 41,500 | 2,900 | 7.51% |
Dec 31, 2004 | 38,600 | 1,400 | 3.76% |
Dec 31, 2003 | 37,200 | 3,800 | 11.38% |
Dec 31, 2002 | 33,400 | 4,400 | 15.17% |
Dec 31, 2001 | 29,000 | 2,000 | 7.41% |
Dec 31, 2000 | 27,000 | 0 | - |
Dec 31, 1999 | 27,000 | 12,000 | 80.00% |
Dec 31, 1998 | 15,000 | -1,300 | -7.98% |
Dec 31, 1997 | 16,300 | -1,500 | -8.43% |
Dec 31, 1996 | 17,800 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
Baxter International | 60,000 |
Illumina | 13,360 |
BeiGene | 10,600 |
BioMarin Pharmaceutical | 3,401 |
Insulet | 3,000 |
Incyte | 2,524 |
Genmab | 2,204 |
Neurocrine Biosciences | 1,400 |
DGX News
- 5 days ago - Quest Diagnostics Releases 2023 Corporate Responsibility Report - PRNewsWire
- 6 days ago - Quest Diagnostics to Acquire Select Lab Assets from Allina Health - PRNewsWire
- 13 days ago - Quest Diagnostics to Release Second Quarter 2024 Financial Results on July 23, 2024 - PRNewsWire
- 21 days ago - Quest Diagnostics Completes Acquisition of Select PathAI Diagnostics' Lab Assets from PathAI, Accelerating Adoption of AI and Digital Pathology to Speed Cancer Diagnosis - PRNewsWire
- 4 weeks ago - Blood-based MRD Test for Cancer Recurrence Can Generate Cost Savings in Colorectal Cancer Treatment, Finds Study in JAMA Health Forum - PRNewsWire
- 6 weeks ago - Quest Diagnostics Elects Robert B. Carter, CIO of FedEx Corporation, to Board of Directors - PRNewsWire
- 6 weeks ago - Quest Diagnostics Declares Quarterly Cash Dividend - PRNewsWire
- 6 weeks ago - Workforce Drug Test Cheating Surged in 2023, Finds Quest Diagnostics Drug Testing Index Analysis of Nearly 10 Million Drug Tests - PRNewsWire